779 patents
Utility
Cell culture process for producing RSV F protein
18 Jan 24
The invention relates to methods for producing an RSV F protein trimer in a fed batch cell culture.
Shelby Hutchins BREEN, Cameron Albert HARRINGTON, Michaela Evelina JACOBS, Jason Arnold LOTVIN, Bhanu Chandra MULUKUTLA, David STEAD, Madhuresh SUMIT
Filed: 30 Sep 21
Utility
System and Method for Needle Hiding In Injectors
18 Jan 24
An injector, comprising a housing arranged along a longitudinal axis and configured to receive a medicament cartridge; an injection drive mechanism for driving a piston, the piston forming part of the medicament cartridge, the injection drive mechanism injecting a medicament when the piston is forwardly displaced; and a needle hiding element, which is slidably attached to the housing and positionable in at least one of an extended orientation and a retracted orientation, wherein in the extended orientation the needle hiding element protrudes forwardly from the housing and in the retracted orientation, the needle hiding element is locked relative to the housing.
Ilan KACHLER, Idan NAAMAN, Amotz PORAT, Tom SHEFER
Filed: 12 Nov 21
Utility
Image-based Disease Diagnostics Using a Mobile Device
18 Jan 24
A diagnostic system performs disease diagnostic tests using at least an optical property modifying device and a mobile device.
Ivan Krastev Dimov, Frank B. Myers, III, John Robert Waldeisen, Debkishore Mitra
Filed: 2 Aug 23
Utility
Therapeutic Antibodies and Their Uses
18 Jan 24
The present invention relates to antibodies that specifically bind to B7-H4 (B7 Homology 4, encoded by gene VTCN1) and bispecific antibodies that specifically bind to both B7-H4 and CD3 (Cluster of Differentiation 3), and polynucleotides, pharmaceutical compositions and methods and uses thereof.
James Reasoner Apgar, Andrea Therese Hooper, Malgorzata Agnieszka Nocula-Lugowska, Lei Wu
Filed: 15 Aug 23
Utility
Therapeutic Antibodies and Their Uses
18 Jan 24
The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3).
Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
Filed: 25 Aug 23
Utility
CD47 Blockade Therapy with CD38 Antibody
18 Jan 24
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab.
Gloria Hoi Ying LIN, Natasja Nielsen VILLER, Mark Michael WONG, Jeffrey Todd WINSTON, Robert Adam UGER
Filed: 30 Aug 23
Utility
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
16 Jan 24
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof.
Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-Ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
Filed: 6 Mar 21
Utility
Self-amplifying Rna Encoding an Influenza Virus Antigen
11 Jan 24
Self-amplifying RNA (saRNA) molecules encoding an influenza virus antigen and methods of use thereof are disclosed herein.
Hui Cai, Ye Che, Fernando Martin Diaz, Raquel Munoz-Moreno, Alicia Solórzano Quijano, Chong Wang
Filed: 6 Jul 23
Utility
IL-12 Variants and Uses Thereof
11 Jan 24
IL-12 variants are provided.
James Reasoner APGAR, Javier Fernando CHAPARRO RIGGERS, Ling Hon Matthew CHU, Tzu-Hsuan HUANG, Kritika MOHAN, Lidia MOSYAK, Edward Derrick PASCUA, James Travis PATTERSON, Gabriel Roy STARBECK-MILLER, Dirk Michael ZAJONC
Filed: 15 Jun 23
Utility
Combination Product for the Treatment of Cancer
11 Jan 24
Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.
Grégoire Vuagniaux, Norbert Wiedemann, Claudio Zanna
Filed: 2 Jun 23
Utility
Methods and Compositions for Inhibiting Excess Nucleic Acid Precipitation
11 Jan 24
The present disclosure describes improved methods for use in purifying biological products made by host cells.
Neha KALLA, William KISH, John LIGHTHOLDER, Zhuo LIU, Eric VORST, Tamara ZEKOVIC
Filed: 17 Dec 21
Utility
Methods and Compositions for Inhibiting Excess Nucleic Acid Precipitation
11 Jan 24
The present disclosure provides improved methods and systems for transfecting host cells with nucleic acids, such as plasmid DNA, for purposes of efficiently producing biological products, such as AAV vectors, at large scale.
Larry Dean DETERMAN, Nathaniel A. JENKINS, Daniel KOBACK, Delaney Kate KOLICH, Paul B. LANTER, Seyed Pouria MOTEVALIAN, Kathryn C. OLSON, Jeffrey William PAVLICEK, Austin Stenhen TRITT, Vincent WINGATE
Filed: 17 Dec 21
Utility
Diacylglycerol acyl transferase 2 inhibitors
9 Jan 24
Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
Filed: 11 Jun 21
Utility
Combination Therapy
4 Jan 24
This invention relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) or a pharmaceutically acceptable salt thereof, and an antiandrogen, optionally in further combination with an additional anti-cancer agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
Lars ANDERS, Kimberly Hyunjung KIM, Danan LI, Elizabeth Anne MCMILLAN, Robert Andrew ROLLINS, Brendan Ayers VEENEMAN
Filed: 10 Aug 21
Utility
3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES As Mek Inhibitors
4 Jan 24
The invention relates to a method of treating a MEK-associated tumor by administering to a subject in need thereof a therapeutically effective amount of a solid form 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.
Shelley ALLEN, Patrick Michael DOERNER BARBOUR, James Francis BLAKE, Sydney Taylor BLANCHE, Mark Laurence BOYS, Wesley Dewitt CLARK, Connor James COWDREY, Joshua Ryan DAHLKE, Alex Andrew KELLUM, Ellen Margaret KNAPP, David Austin MORENO, Jacob Matthew O'LEARY, Li REN, Faith Elizabeth WITKOS, Jennifer Lynn FULTON
Filed: 18 Sep 23
Utility
Immunogenic Compositions for Use In Pneumococcal Vaccines
4 Jan 24
An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 15, while limiting the number of conjugates.
Annaliesa Sybil Anderson, Seema Shridhar Gangolli, Kathrin Ute Jansen, Avvari Krishna Prasad, Michael William Pride, Ingrid Lea Scully, Wendy Jo Watson
Filed: 1 Nov 21
Utility
Coronavirus Vaccine
4 Jan 24
The present disclosure relates to the fields of packaging, transportation, and storage of temperature-sensitive materials, such as biological and/or pharmaceutical products.
Marjoh Nauta, Dirk Jozef Peeters, Tom Frank Steven Van Doorslaer, Advait Vijay Badkar, Ramin Darvari, Nicholas William Warne, James Jean, Danny Pierre G. Hendrikse, Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
Filed: 16 Apr 21
Utility
Methods for Measuring Dystrophin In Tissue Samples
4 Jan 24
Embodiments described herein provide a solution to the measurement of various dystrophins expressed in a cell or tissue.
Vahid FARROKHI, Hendrick NEUBERT, Joe PALANDRA, Jason Michael WALSH
Filed: 21 Oct 21
Utility
Human cytomegalovirus GB polypeptide
2 Jan 24
The present invention comprises mutants of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB), compositions including the mutants and uses thereof.
Yuhang Liu, Ye Che, Xiaoyuan Sherry Chi, Philip Ralph Dormitzer, Jennifer Anne Nicki, Xiaojie Yao
Filed: 17 Jun 21
Utility
GLP-1 receptor agonists and uses thereof
2 Jan 24
Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Gary Erik Aspnes, Scott W. Bagley, Edward L. Conn, John M. Curto, David J. Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Filed: 13 Jun 19